Role of programmed death‐ligand 1 in predicting the treatment outcome of salvage chemotherapy after nivolumab in recurrent/metastatic head and neck squamous cell carcinoma

Head & Neck ◽  
2020 ◽  
Vol 42 (11) ◽  
pp. 3275-3281
Author(s):  
Yushi Ueki ◽  
Takeshi Takahashi ◽  
Hisayuki Ota ◽  
Ryusuke Shodo ◽  
Keisuke Yamazaki ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Treatment Outcome ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Salvage Chemotherapy ◽  
Neck Squamous Cell Carcinoma ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

scholarly journals The Role of the Programmed Death Receptor-1/Programmed Death Ligand-1: Immunologic Checkpoint in Human Papillomavirus–Associated Head and Neck Squamous Cell Carcinoma

2018 ◽  
Vol 142 (6) ◽  
pp. 719-720
Author(s):  
Christine Kunkle ◽  
Flavia G Rosado
Keyword(s):  
Squamous Cell Carcinoma ◽  
Human Papillomavirus ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Death Receptor ◽  
Neck Squamous Cell Carcinoma ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

Context.— There has been increasing interest in understanding the role of programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) pathway in cancer biology and its clinical significance in cancer therapy. Objective.— To discuss the studies of the PD-1/PD-L1 pathway in human papillomavirus–positive head and neck squamous cell carcinoma, focusing on the pathogenesis of cancer, characterization of the tumor microenvironment, and the effect of such studies in laboratory medicine. Data sources.— Data sources included peer-reviewed literature and reputable online sources. Conclusions.— To date, there are few studies of PD-1 and PD-L1 in human papillomavirus–positive head and neck squamous cell carcinoma. There is evidence that the PD-1/PD-L1 pathway has a role in this type of cancer; however, further studies are needed to better characterize the effect of the human papillomavirus and its use as a marker of therapy response.

scholarly journals Changes in programmed death-ligand 1 expression during cisplatin treatment in patients with head and neck squamous cell carcinoma

Oncotarget ◽  
2017 ◽  
Vol 8 (58) ◽  
pp. 97920-97927 ◽  
Author(s):  
Chan-Young Ock ◽  
Sehui Kim ◽  
Bhumsuk Keam ◽  
Soyeon Kim ◽  
Yong-Oon Ahn ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
Programmed Death Ligand 1 ◽  
Programmed Death

scholarly journals Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Areeg Elmusrati ◽  
Justin Wang ◽  
Cun-Yu Wang
Keyword(s):  
Squamous Cell Carcinoma ◽  
Immune System ◽  
Tumor Microenvironment ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Neck Squamous Cell Carcinoma ◽  
High Morbidity ◽  
Advanced Therapies

AbstractHead and neck squamous cell carcinoma (HNSCC), an aggressive malignancy, is characterized by high morbidity and low survival rates with limited therapeutic options outside of regional surgery, conventional cytotoxic chemotherapy, and irradiation. Increasing studies have supported the synergistic role of the tumor microenvironment (TME) in cancer advancement. The immune system, in particular, plays a key role in surveillance against the initiation, development, and progression of HNSCC. The understanding of how neoplastic cells evolve and evade the immune system whether through self-immunogenicity manipulation, or expression of immunosuppressive mediators, provides the foundation for the development of advanced therapies. Furthermore, the crosstalk between cancer cells and the host immune system have a detrimental effect on the TME promoting angiogenesis, proliferation, and metastasis. This review provides a recent insight into the role of the key inflammatory cells infiltrating the TME, with a focus on reviewing immunological principles related to HNSCC, as cancer immunosurveillance and immune escape, including a brief overview of current immunotherapeutic strategies and ongoing clinical trials.

Sign in / Sign up

Export Citation Format

Share Document